

CLAES W. HORNSTRAND



Claes W. Hornstrand is the President and CEO of Wildwood Therapeutics, Inc., a Thousand Oaks-based biotech startup with seed funding from Westlake Village Biopartners (www.westlakebio.com).

Prior to this Mr. Hornstrand spent 21 years at Amgen. He has extensive U.S., regional, and global strategic commercial experience based on the depth and breadth of responsibilities and leadership roles he held throughout his career in biotech. His last role at Amgen was V.P. and Head of global value, access, and policy leading a team of 150 professionals worldwide. He served on the CEO operating team and Amgen's Portfolio Guidance Team where financial and strategic decisions on the company pipeline were made. Prior to that he was the V.P. and head of U.S. value, access, and pricing. Prior to that he was V.P. and Global Product General Manager for one of Amgens key oncology therapeutics, Kyprolis.

Prior to this, Mr. Hornstrand served in several additional therapeutic leadership roles in U.S. and global marketing, business development, U.S sales, U.S. and global value, access, and policy.

Previous to working at Amgen, Mr. Hornstrand worked at Abbott Laboratories for 10 years, where he served in various sales, marketing and business development roles, both in the U.S. as well as overseas.

Prior to working at Abbott, Mr. Hornstrand worked at McKinsey & Company for 2 years, where he served as a Consultant, and worked on a series of engagements in a variety of industries.

Mr. Hornstrand received a master's degree in Business Administration from University of Illinois in 1989 and a master's degree in Mechanical Engineering from the Royal Institute of Technology, Stockholm, in 1987. Mr. Hornstrand is a Fulbright Scholar and is fluent in English, Swedish and German.